By Katarina A. Lewczyk | Date Published: June 18, 2024
Shyam Patel and Trainees Study Relapsed Follicular Lymphoma Treatment in Recent Publication
Follicular lymphoma is one of the most common subtypes of non-Hodgkin lymphoma in the United States. Some patients achieve remission after first-line chemotherapy, but some patients have resistant disease. Once resistance develops, it can become challenging to treat the disease, however, in recent years, many new targeted therapies have become available.
In a recent study published in Leukemia Research, Shyam Patel, MD, PhD, assistant professor of medicine in the Division of Hematology/Oncology, Vera Kazakova, MD, a second-year Hematology/Oncology fellow, Benjamin Tanenbaum, MD, a third-year Internal Medicine Resident, and Benyamin Yaniv, MD, a second-year Internal Medicine Resident, explore the latest treatments for relapsed follicular lymphoma and how new immunotherapies may be able to help patients who are resistant to first-line therapy. Additionally, Dr. Patel and his team will focus on how lymphoma microenvironments can be targeted therapeutically and explore where the field is headed in the near future.